Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press5810.17650/1994-4098-2013-0-3-4-54-59MAMMOLOGY. TREATMENTМАММОЛОГИЯ. ЛЕЧЕНИЕThe role of Taxotere in adjuvant therapy for early breast cancerРоль Таксотера в адъювантной терапии раннего рака молочной железыKolyadinaI. V.КолядинаИ. В.
Russian Federation
irinakolyadina@yandex.ruPoddubnayaI. V.ПоддубнаяИ. В.
Russian Federation
Oncology Chair, Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia, MoscowКафедра онкологии ГБОУ ДПО РМАПО Минздрава России, Москва220920133-4545922072014220720142013https://ojrs.abvpress.ru/ojrs/article/view/58

In the present review has described the historical stages of systemic therapy of breast cancer with the use of taxanes, and has given a detailed description of drugs (paclitaxel and docetaxel). The role of docetaxel (Taxotere) in reducing the recurrences and death from cancer risk has shown. The major randomized trials has described; was studied the effectiveness of combination with docetaxel (Taxotere) in the adjuvant treatment of early breast cancer with or without lymph nodes involvement. The important role of docetaxel (Taxotere) in the adjuvant treatment of HER2-positive breast cancer was shown.

В представленном обзоре описаны исторические этапы лекарственной терапии рака молочной железы (РМЖ) с использованием таксанов, дана подробная характеристика препаратов (паклитаксела и доцетаксела), показана роль доцетаксела (Таксотера) в снижении риска рецидива болезни и смерти от ее прогрессирования. Описаны крупные рандомизированные исследования, в ко- торых изучена эффективность комбинаций с доцетакселом (Таксотером) в адъювантной терапии ранних стадий РМЖ c нали- чием и отсутствием поражения регионарных лимфатических узлов. Показана важная роль доцетаксела (Таксотера) в адъю- вантном лечении HER-2-позитивного РМЖ.

early breast canceradjuvant chemotherapydocetaxel (Taxotere)the risk of recurrence and death from progressionранний рак молочной железыадъювантная химиотерапиядоцетаксел (Таксотер)риск рецидива и смерти от прогрессирования1. Lavelle F., Gueritte-Voegelein F., Guenard D. Taxotere: from yew's needles to clinical practice. Bull Cancer 1993;80(4):326–38.Lavelle F., Gueritte-Voegelein F., Guenard D. Taxotere: from yew's needles to clinical practice. Bull Cancer 1993;80(4):326–38.2. Hanauske A.R., Degen D., Hilsenbeck S.G. et al. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 1992;3(2):121–4.Hanauske A.R., Degen D., Hilsenbeck S.G. et al. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 1992;3(2):121–4.3. Rowinsky E.K., Onetto N., Canetta R.M., Arbuck S.G. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992;19(6):646–62.Rowinsky E.K., Onetto N., Canetta R.M., Arbuck S.G. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992;19(6):646–62.4. Arioka H., Saijo N. Microtubules and anti- neoplastic drugs. Gan To Kagaku Ryoho 1994;21(5):583–90.Arioka H., Saijo N. Microtubules and anti- neoplastic drugs. Gan To Kagaku Ryoho 1994;21(5):583–90.5. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet 1994;344(8932):1267–72.Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet 1994;344(8932):1267–72.6. Hanauske A.R., Depenbrock H., Shirvani D., Rastetter J. Effects of the microtubule-disturb- ing agents docetaxel (Taxotere), vinblastine and vincristine on epidermal growth factor-re- ceptor binding of human breast cancer cell lines in vitro. Eur J Cancer 1994;30A(11):1688–94.Hanauske A.R., Depenbrock H., Shirvani D., Rastetter J. Effects of the microtubule-disturb- ing agents docetaxel (Taxotere), vinblastine and vincristine on epidermal growth factor-re- ceptor binding of human breast cancer cell lines in vitro. Eur J Cancer 1994;30A(11):1688–94.7. Hill B.T., Whelan R.D., Shellard S.A. et. al. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and cer- tain drug resistant sublines in vitro. Invest New Drugs 1994;12(3):169–82.Hill B.T., Whelan R.D., Shellard S.A. et. al. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and cer- tain drug resistant sublines in vitro. Invest New Drugs 1994;12(3):169–82.8. Bissery M.C., Guenard D., Gueritte- Volgelein F., Lavelle F. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol anologue. Canc Res 1991;51(18):4845– 52.Bissery M.C., Guenard D., Gueritte- Volgelein F., Lavelle F. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol anologue. Canc Res 1991;51(18):4845– 52.9. Harrison S.D., Dykes D.J., Shepherd R.V., Bissery M.C. Response of human xenografts to taxotere. Proc AACR 1992;33:526.Harrison S.D., Dykes D.J., Shepherd R.V., Bissery M.C. Response of human xenografts to taxotere. Proc AACR 1992;33:526.10. Bissery M.C., Nohynec G., Sanderink G.J., Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part 1: pre- clinical experience. Anticancer Drugs 1995;6(3):339–68.Bissery M.C., Nohynec G., Sanderink G.J., Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part 1: pre- clinical experience. Anticancer Drugs 1995;6(3):339–68.11. Hortobagyi G.N. Recent progress in the clinical development of docetaxel. Semin Oncol 1999;26(3 Suppl 9):32–6.Hortobagyi G.N. Recent progress in the clinical development of docetaxel. Semin Oncol 1999;26(3 Suppl 9):32–6.12. Mamounas E.P. NSABP Protocol B-27. Preoperative doxorubicin plus cyclophospha- mide followed by preoperative or postopera- tive docetaxel. Oncology (Williston Park) 1997;11(6 Suppl 6):37–40.Mamounas E.P. NSABP Protocol B-27. Preoperative doxorubicin plus cyclophospha- mide followed by preoperative or postopera- tive docetaxel. Oncology (Williston Park) 1997;11(6 Suppl 6):37–40.13. Nabholtz J.M., Mackey J., Smylie M., Tonkin K. Taxane-based three-drug combina- tion in metastatic and adjuvant treatment of breast cancer. Semin Oncol 1998;25(5 Suppl 12):27–31.Nabholtz J.M., Mackey J., Smylie M., Tonkin K. Taxane-based three-drug combina- tion in metastatic and adjuvant treatment of breast cancer. Semin Oncol 1998;25(5 Suppl 12):27–31.14. Costa S.D., von Minckwitz G., Raab G. et al. The role of docetaxel (Taxotere) in neoadjuvantCosta S.D., von Minckwitz G., Raab G. et al. The role of docetaxel (Taxotere) in neoadjuvantchemotherapy of breast cancer. Semin Oncol 1999;26(3 Suppl 9):24–31.15. Figgitt D.P., Wiseman L.R. Docetaxel: an update of its use in advanced breast cancer. Drugs 2000;59(3):621–51.Figgitt D.P., Wiseman L.R. Docetaxel: an update of its use in advanced breast cancer. Drugs 2000;59(3):621–51.16. Колядина И.В., Макаренко Н.П., Поддубная И.В. Роль таксотера в лечении метастатического рака молочной железы. Совр онкол 2009;2(11):10–2.Колядина И.В., Макаренко Н.П., Поддубная И.В. Роль таксотера в лечении метастатического рака молочной железы. Совр онкол 2009;2(11):10–2.17. Mackey J.R., Martin M., Pienkowski T. et al. Adjuvant docetaxel, doxorubicin, and cy- clophosphamide in node-positive breast can- cer: 10-year follow-up of the phase 3 ran- domised BCIRG 001 trial. Lancet Oncol 2013;14(1):72–80.Mackey J.R., Martin M., Pienkowski T. et al. Adjuvant docetaxel, doxorubicin, and cy- clophosphamide in node-positive breast can- cer: 10-year follow-up of the phase 3 ran- domised BCIRG 001 trial. Lancet Oncol 2013;14(1):72–80.18. Ozdemir N., Aksoy S., Zengin N., Altundag K. Taxanes in the adjuvant treatment of node-negative breast cancer patients. J BUON 2012;17(1):27–32.Ozdemir N., Aksoy S., Zengin N., Altundag K. Taxanes in the adjuvant treatment of node-negative breast cancer patients. J BUON 2012;17(1):27–32.19. Jones S.E., Collea R., Paul D. et al. Adju- vant docetaxel and cyclophosphamide plus trastuzumab in patients with HER-2-amplified early stage breast cancer: a single-group, open- label, phase 2 study. LancetJones S.E., Collea R., Paul D. et al. Adju- vant docetaxel and cyclophosphamide plus trastuzumab in patients with HER-2-amplified early stage breast cancer: a single-group, open- label, phase 2 study. LancetOncol 2013;14(11):1121–28.20. Bulent Akinci M., Algin E., Inal A. et al. Sequential adjuvant docetaxel and anthracy- cline chemotherapy for node positive breast cancers: a retrospective study. J BUON 2013;18(2):314–20.Bulent Akinci M., Algin E., Inal A. et al. Sequential adjuvant docetaxel and anthracy- cline chemotherapy for node positive breast cancers: a retrospective study. J BUON 2013;18(2):314–20.21. Yuan P., Xu B.H., Wang J.Y. et al. Docetax- el plus carboplatin versus EC-T as adju-Yuan P., Xu B.H., Wang J.Y. et al. Docetax- el plus carboplatin versus EC-T as adju-vant chemotherapy for triple-negative breast cancer: safety data from a phase III random- ized open-label trial. Zhonghua Zhong Liu Za Zhi 2012;34(6):465–8.22. Coudert B., Asselain B., Campone M. et al. Extended benefit from sequential administra- tion of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow- up results of the UNICANCER-PACS01 trial. Oncologist 2012;17(7):900–9.Coudert B., Asselain B., Campone M. et al. Extended benefit from sequential administra- tion of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow- up results of the UNICANCER-PACS01 trial. Oncologist 2012;17(7):900–9.23. Eiermann W., Pienkowski T., Crown J. et al. Phase III study of doxorubicin/cyclophospha- mide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 2011;29(29):3877–84.Eiermann W., Pienkowski T., Crown J. et al. Phase III study of doxorubicin/cyclophospha- mide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 2011;29(29):3877–84.24. Jones S., Holmes F.A., O'Shaughnessy J. et al. Docetaxel With Cyclophosphamide Is As- sociated With an Overall Survival Benefit Com- pared With Doxorubicinand Cyclophospha- mide: 7-Year Follow-Up of USJones S., Holmes F.A., O'Shaughnessy J. et al. Docetaxel With Cyclophosphamide Is As- sociated With an Overall Survival Benefit Com- pared With Doxorubicinand Cyclophospha- mide: 7-Year Follow-Up of USOncology Research Trial 9735. J Clin Oncol 2009;27(8):1177–83.25. De Laurentiis M., Cancello G., D’Agostino D. et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta- analysis of randomized trials. J Clin Oncol 2008;26(1):44–53.De Laurentiis M., Cancello G., D’Agostino D. et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta- analysis of randomized trials. J Clin Oncol 2008;26(1):44–53.26. Martín M., Seguí M.A., Antón A. et al. Ad- juvant docetaxel for high-risk, node-nega-Martín M., Seguí M.A., Antón A. et al. Ad- juvant docetaxel for high-risk, node-nega-tive breast cancer. N Engl J Med 2010;363(23):2200–10.27. Slamon D.J., Clark G.M., Wong S.G. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235(4785):177–82.Slamon D.J., Clark G.M., Wong S.G. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235(4785):177–82.28. Slamon D.J., Godolphin W., Jones L.A. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244(4905):707–12.Slamon D.J., Godolphin W., Jones L.A. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244(4905):707–12.29. De Luca A., Carotenuto A., Rachiglio A. et al. The role of the EGFR signaling in tumor mi- croenvironment. J Cell Physiol 2008;214(3):559–67.De Luca A., Carotenuto A., Rachiglio A. et al. The role of the EGFR signaling in tumor mi- croenvironment. J Cell Physiol 2008;214(3):559–67.30. Piccart-Gebhart M.J., Procter M., Leyland-Jones B. et al. Trastuzumab after adju- vant chemotherapy in HER-2-positive breast cancer. N Engl J Med 2005;353(16):1659–72.Piccart-Gebhart M.J., Procter M., Leyland-Jones B. et al. Trastuzumab after adju- vant chemotherapy in HER-2-positive breast cancer. N Engl J Med 2005;353(16):1659–72.31. Romond E.H., Perez E.A., Bryant J. et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer. N Engl J Med 2005;353(16):1673–84.Romond E.H., Perez E.A., Bryant J. et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer. N Engl J Med 2005;353(16):1673–84.32. Joensuu H., Kellokumpu-Lehtinen P.-L., Bono P. et al. Adjuvant docetaxel or vinorel- bine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809–20.Joensuu H., Kellokumpu-Lehtinen P.-L., Bono P. et al. Adjuvant docetaxel or vinorel- bine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809–20.33. Gennari A., Sormani M.P., Pronzato P. et al. HER-2 status and efficacy of adjuvant anthra- cyclines in early breast cancer: A pooled analy- sis of randomized trials. J Natl Cancer Inst 2008;100(1):14–20.Gennari A., Sormani M.P., Pronzato P. et al. HER-2 status and efficacy of adjuvant anthra- cyclines in early breast cancer: A pooled analy- sis of randomized trials. J Natl Cancer Inst 2008;100(1):14–20.34. Pritchard K.I., Messersmith H., Elavathil L. et al. HER-2 and topoisomerase II as predic- tors of response to chemotherapy. J Clin Oncol 2008;26(5):736–744.Pritchard K.I., Messersmith H., Elavathil L. et al. HER-2 and topoisomerase II as predic- tors of response to chemotherapy. J Clin Oncol 2008;26(5):736–744.35. Slamon D., Eiermann W., Robert N. et al. Adjuvant trastuzumab in HER-2-positive breast cancer. N Engl JSlamon D., Eiermann W., Robert N. et al. Adjuvant trastuzumab in HER-2-positive breast cancer. N Engl JMed 2011;365(14):1273–83.36. Au H.J., Eiermann W., Robert N.J., Pienkowski T. et al. Health-related quality of life with adjuvant docetaxel- and trastuzumab- based regimens in patients with node-positive and high-risk node-negative, HER-2-positive early breast cancer: results from the BCIRG 006 Study. Oncologist 2013;18(7):812–8.Au H.J., Eiermann W., Robert N.J., Pienkowski T. et al. Health-related quality of life with adjuvant docetaxel- and trastuzumab- based regimens in patients with node-positive and high-risk node-negative, HER-2-positive early breast cancer: results from the BCIRG 006 Study. Oncologist 2013;18(7):812–8.